

Supplementary materials

Table 1. Baseline characteristics of the study population of different genders

Characteristics	Male (n=95)	Female (n=67)	P value
Age	32±11	34±14	0.311
Disease activity (active)	57 (60.0%)	36 (53.7%)	0.427
Body Mass Index	20.0±4.3	19.7±3.6	0.641
Employment status	-	-	
no	26 (27.4%)	22 (32.8%)	0.448
retired	4 (4.2%)	5 (7.5%)	
yes	65 (68.4%)	40 (59.7%)	
Living status	-	-	
alone	5 (5.3%)	4 (6.0%)	0.847
with others	90 (94.7%)	63 (94.0%)	
Education	-	-	
up to 6 years	4 (4.2%)	5 (7.5%)	0.776
up to 9 years	26 (27.4%)	20 (29.8%)	
up to 12 years	48 (50.5%)	30 (44.8%)	
college	17 (17.9%)	12 (17.9%)	
Marital status	-	-	
married/cohabitating	52 (54.7%)	35 (52.2%)	0.736
widowed/divorced	8 (8.4%)	4 (6.0%)	
single	35 (36.9%)	28 (41.8%)	
Montreal location	-	-	
Ileal (L1)	33 (34.7%)	30 (44.8%)	0.674
Colonic (L2)	12 (12.6%)	8 (11.9%)	
Ileocolon (L3)	45 (47.4%)	27 (40.3%)	
upper gastrointestinal tract (L4)	1 (1.1%)	0 (0%)	
L4+L1/L2/L3	4 (4.2%)	2 (3.0%)	
Perianal disease	36 (37.9%)	27 (40.3%)	0.757
Current therapy	-	-	
no treatment	0 (0%)	2 (3.0%)	0.497
corticosteroids	9 (9.5%)	6 (8.9%)	
5-aminosalicylates	20 (21.1%)	18 (26.9%)	
immunomodulators	29 (30.5%)	20 (29.9%)	
antitumor necrosis factor	17 (17.8%)	8 (11.9%)	
combined therapy	20 (21.1%)	13 (19.4%)	
Anemia	-	-	
no	63 (66.3%)	28 (41.8%)	0.021
mild	27 (28.4%)	32 (47.8%)	
moderate	4 (4.2%)	5 (7.5%)	
severe	1 (1.1%)	2 (2.9%)	
Relapses in the last year	-	-	
0	26 (27.4%)	22 (32.8%)	0.020
1-2	42 (44.2%)	39 (58.2%)	
3	12 (12.6%)	4 (6.0%)	
≥4	15 (15.8%)	2 (3.0%)	
Disease duration (months)	13±25	11±19	0.582
C-reactive protein	13.2±24.7	11.5±18.5	0.634

Note: Data are presented as the number (%) or mean±standard deviation. CD, Crohn's disease.